Ibrahim, Ali
Moukalled, Nour
Mahfouz, Rami
El Cheikh, Jean
Bazarbachi, Ali
Abou Dalle, Iman http://orcid.org/0000-0002-6520-9134
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
https://doi.org/10.1007/s44228-022-00001-x
Article History
Received: 6 December 2021
Accepted: 24 February 2022
First Online: 12 May 2022
Declarations
:
: I.A received honorarium from Novartis, Amgen and Abbvie and participated in advisory board for Novartis, and Merck. Other authors have no relevant conflict of interest. The authors declare no conflict of interest.
: The study was done in accordance to the declaration of Helsinki, and was approved by the institutional Review Board committee at the American university of Beirut.